Dow Jones
31.267,06 +229,38 (+0,74%) Nasdaq
11.588,56 +226,71 (+2,00%) Nikkei 225
26.490,53 +382,88 (+1,47%) EUR/USD
1,0162 -0,0023 (-0,22%) BTC-EUR
20.703,52 +556,86 (+2,76%) CMC Crypto 200
458,82 +14,50 (+3,26%)
Abeona Therapeutics Inc. (0H7R.L)
| Chiusura precedente | 0,1980 |
| Aperto | 0,1902 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,1902 - 0,1940 |
| Intervallo di 52 settimane | 0,1902 - 0,1940 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 5,42M |
| Beta (5 anni mensile) | 1,50 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8080 |
| Prossima data utili | 27 lug 2022 - 01 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p.m. EDT. A live webcast of the presentation will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 3
- GlobeNewswire
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market und
- GlobeNewswire
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome
